Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CiRA, Dainippon Sumitomo Pharma ink research partnership
CiRA and DSP aim to utilize induced pluripotent stem cells (iPS cells) for idenfying the pathognomonic mechanism of the disease, identify the most disease-specific target molecule from various
CiRA and DSP aim to utilize induced pluripotent stem cells (iPS cells) for idenfying the pathognomonic mechanism of the disease, identify the most disease-specific target molecule from various
Under the agreement, Alkem will get commercialization rights for Karo Bio’s eprotirome across India and other countries in Asia-Pacific and Africa.. In connection to receive Indian marketing approval
The URAC accreditation program offers third-party assurance for employers and consumers that quality standards are met for consumer protection and empowerment, appropriate access to drugs and pharmacies, patient
KP106 is composed of d-amphetamine and a ligand. In clinical studies, KP106 demonstrated pharmacokinetics indicative of an attenuated amphetamine exposure as compared to Vyvanse. MonoSol Rx will have
Taro Pharma is a pharmaceutical company engaged in the discovery, development, manufacturing and marketing of the healthcare products. Earlier, FDA issued warning letter to the company in connection
Femara lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body. The launch
Pharmatek has acquired a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. The technology can be used for both oral and parenteral dosage
TBDxV provides automated computer-aided analysis for a clinician; specifically displaying acid-fast tuberculosis (TB) bacteria using Signature Mapping’s advanced computer vision and pattern recognition technologies. Signature Mapping TBDxV software
The drugs are being distributed by American Regent subsidiary and Animal Health Division. The company’s decision follows the US food and Drug Administration’s (FDA) inspection and its meeting
CNV2197944 is a small molecule, state-dependent calcium channel blocker, intended to selectively inhibit highly active Cav2.2 channels. In preclinical studies, CNV2197944 has demonstrated safety and efficacy profile. Convergence